7-OH Kratom Split Turns Into a Statewide Crackdown

7-OH kratom – Kratom advocates who once beat back a proposed federal ban are now clashing with each other over 7-hydroxymitragynine (7-OH), an ultra-potent kratom concentrate. As consumers report brutal withdrawal and overdoses emerge, federal officials push for Schedule I

For years. kratom supporters told a simple story: a Southeast Asian plant. pain-relieving effects. and a potential safer alternative to pills in the opioid era. They fought a proposed U.S. Drug Enforcement Administration ban a decade ago and won an unusually broad. bipartisan coalition—enough allies to help shape a billion-dollar industry.

Now the fight has moved inside the kratom tent.

Many of the same pro-kratom activists are calling for a ban on products containing concentrates of one kratom active component: 7-hydroxymitragynine. known as 7-OH. It’s an ultra-potent extract. and the argument on the other side is that it behaves like an opioid once it’s in the marketplace—especially when it’s sold in forms such as gummies. capsules. and shots.

“This is a chemically manipulated, full-blown opioid that is now in the marketplace,” says Mac Haddow, senior public policy fellow at the American Kratom Association, a kratom industry lobby group. “They masquerade as kratom products.”

Over the past few years, 7-OH has spread widely. The products have appeared across thousands of gas stations and corner stores. branded with names such as Magic 7OH. 7 O’Heaven. and Pure OHMS. The message consumers are hearing from the product labels may sound familiar to people who already use kratom—but the people trying to quit say they’re dealing with something harsher.

Consumers of 7-OH have spoken about excruciating withdrawal symptoms. There have also been reports of polydrug overdoses involving 7-OH and other substances, and some users say they’re entering rehab to treat dependency. Others are trying to self-detox, relying on advice from Redditors.

In that swirl of personal fallout, the split threatens to pull the broader kratom movement into a regulatory fight it can’t afford to lose. The kratom community fears that a bad reputation tied to 7-OH could drag the entire industry into a regulatory quagmire.

But the 7-OH industry has organized against prohibition, making a counterclaim that sits at the center of the conflict: 7-OH is kratom.

They argue that 7-OH only appears in trace amounts within the leaves of the plant, and that the benefits as an analgesic outweigh the potential harms. Proponents of 7-OH see the substance and the plant as inseparably connected.

At testimony to Colorado legislators in April 2025, Michele Ross—chief scientific adviser to the 7-HOPE Alliance, a 7-OH advocacy group—wrote, “To say 7-OH is not kratom is to say caffeine is not coffee or THC is not cannabis. It simply does not make sense.”

To other researchers, that analogy glosses over a key difference: unlike coffee, cannabis, and kratom—consumed for centuries if not thousands of years—7-OH doesn’t have a long history of human use. It has only been on the market for a few years.

Chris McCurdy. a leading kratom researcher and director of the University of Florida’s translational drug development core. points to the products themselves. not just the plant they claim to come from. “So. these products. while represented as ‘clean’ are anything but. ” he says. explaining that many products labeled as 7-OH contain compounds with unknown biological effects in animals or humans.

The political pressure is hardening the divide. Federal messaging has exacerbated tensions between the two sides, turning a debate over chemistry into a battle over enforcement.

Last July, U.S. Health and Human Services secretary Robert F. Kennedy Jr. described the 7-OH industry as “sinister” at a press conference. At the same event, FDA commissioner Marty Makary called for the DEA to categorize the drug as Schedule I—the most restrictive class of banned substances.

Then on May 11, President Donald Trump endorsed “natural 7-OH” publicly in remarks from the Oval Office. The comments were confusing and appeared to refer to kratom.

Proponents and critics also accuse top advocates and enforcers of having personal entanglements with the industry. It appears that both RFK Jr. and Department of Homeland Security secretary Markwayne Mullin—who is also pushing for a 7-OH crackdown—have strong ties to a kratom lobbyist. a convicted criminal. behind a notorious kratom drinks company.

This is the part of the story that makes everything feel like it’s happening faster than the public can keep up: federal officials weigh sweeping scheduling while lawmakers and states act on their own.

A dozen states—from California to Vermont—have already moved ahead of federal scheduling with their own 7-OH bans. Seven of those states have also banned kratom, though Rhode Island recently overturned its prohibition.

Taken together, the pattern is stark. A plant that once carried the promise of opioid-era relief now sits beside an extract that critics say functions too much like an opioid—while both sides fight for the same regulatory outcome. For consumers caught in the middle. the debate isn’t academic; it’s what happens after the product is in the body. and what it feels like to try to stop.

Whether 7-OH ends up treated as “kratom” or as something closer to a Schedule I drug may determine the fate of an entire category of storefront and online sales. But the immediate impact is already being felt in withdrawal experiences. rehab admissions. and the growing urgency among people trying to make their next decision about what they put in their bodies.

kratom 7-hydroxymitragynine 7-OH DEA FDA Schedule I American Kratom Association opioid epidemic withdrawal overdoses 7-HOPE Alliance Colorado legislators state bans